Abstract
Historically, DNA has been the target for many metal-based anti-cancer drugs, but drawbacks of prevailing therapies have stimulated the search for new molecular targets which may present unique opportunities for therapeutic exploitation. Enzyme inhibition has recently been identified as an alternative and significant target. The pursuit of novel metallodrug candidates that selectively target enzymes is now the subject of intense investigation in medicinal bioinorganic chemistry and chemical biology. In the field of drug design, it is recognised by many that exploiting the structural and chemical diversity of metal ions for the identification of potential hit and lead candidates can dramatically increase the number of possible drug candidates that may be added to the already abundant armoury of chemotherapeutic agents. This review will focus on recent key advancements in enzyme inhibition as a key target for the development of novel metal-based anti-cancer therapeutics. The enormous clinical success of classical platinum drugs, amongst others, coupled with the wealth of knowledge accumulated in recent years on enzyme structure and function, has undoubtedly been the impetus behind the development of new metallodrug candidates with enzyme inhibitory properties. Recent trends in this field will be reviewed with a particular emphasis on metal complexes that inhibit protein and lipid kinases, matrix metalloproteases, telomerases, topoisomerases, glutathione-Stransferases, and histone deacetylases.
Keywords: Cancer, chaperone, drug development, enzyme inhibitor, medicinal bioinorganic chemistry, metallodrugs, metals, target
Anti-Cancer Agents in Medicinal Chemistry
Title: Enzyme Inhibition as a Key Target for the Development of Novel Metal-Based Anti-Cancer Therapeutics
Volume: 10 Issue: 5
Author(s): Darren Griffith, James P. Parker and Celine J. Marmion
Affiliation:
Keywords: Cancer, chaperone, drug development, enzyme inhibitor, medicinal bioinorganic chemistry, metallodrugs, metals, target
Abstract: Historically, DNA has been the target for many metal-based anti-cancer drugs, but drawbacks of prevailing therapies have stimulated the search for new molecular targets which may present unique opportunities for therapeutic exploitation. Enzyme inhibition has recently been identified as an alternative and significant target. The pursuit of novel metallodrug candidates that selectively target enzymes is now the subject of intense investigation in medicinal bioinorganic chemistry and chemical biology. In the field of drug design, it is recognised by many that exploiting the structural and chemical diversity of metal ions for the identification of potential hit and lead candidates can dramatically increase the number of possible drug candidates that may be added to the already abundant armoury of chemotherapeutic agents. This review will focus on recent key advancements in enzyme inhibition as a key target for the development of novel metal-based anti-cancer therapeutics. The enormous clinical success of classical platinum drugs, amongst others, coupled with the wealth of knowledge accumulated in recent years on enzyme structure and function, has undoubtedly been the impetus behind the development of new metallodrug candidates with enzyme inhibitory properties. Recent trends in this field will be reviewed with a particular emphasis on metal complexes that inhibit protein and lipid kinases, matrix metalloproteases, telomerases, topoisomerases, glutathione-Stransferases, and histone deacetylases.
Export Options
About this article
Cite this article as:
Griffith Darren, P. Parker James and J. Marmion Celine, Enzyme Inhibition as a Key Target for the Development of Novel Metal-Based Anti-Cancer Therapeutics, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (5) . https://dx.doi.org/10.2174/1871520611009050354
DOI https://dx.doi.org/10.2174/1871520611009050354 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biological Therapies: Effects of Proinflammatory Pathways and their Inhibition on the Myocardium of Rheumatoid Athritis Patients
Current Medicinal Chemistry The Role of Adenosine in Alzheimers Disease
Current Neuropharmacology The Future of Induced Pluripotent Stem Cells for Cardiac Therapy and Drug Development
Current Pharmaceutical Design New Achievements in Bioinformatics Prediction of Post Translational Modification of Proteins
Current Topics in Medicinal Chemistry Immunoregulatory Impact of Food Antioxidants
Current Pharmaceutical Design Arterial Stiffness As A Therapeutic Target For Isolated Systolic Hypertension: Focus on Vascular Calcification and Fibrosis
Current Hypertension Reviews MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Antiviral Drug Discovery Targeting to Viral Proteases
Current Pharmaceutical Design Nitric Oxide-Mediated Endothelial Dysfunction - Is there Need to Treat?
Current Vascular Pharmacology Innovative Formulations for the Controlled and Site-specific Delivery of Antiinflammatory Drugs
Current Pharmaceutical Design The Role of Lymphotoxin Receptor Signaling in Diseases
Current Molecular Medicine Endothelial Dysfunction and Coronary Artery Spasm
Current Drug Targets - Cardiovascular & Hematological Disorders Circulating Biochemical Markers of Brain Damage in Infants Complicated by Ischemia Reperfusion Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Circulating Levels of Uric Acid and Risk for Metabolic Syndrome
Current Diabetes Reviews Lipid-Induced Modulation of Protective Signalling Pathways in Cardiovascular Disease: The Role of High Density Lipoproteins
Current Signal Transduction Therapy AMPK - Activated Protein Kinase and its Role in Energy Metabolism of the Heart
Current Cardiology Reviews Contemporary Treatment of Amyloid Heart Disease
Current Pharmaceutical Design Editorial (Thematic Issue: The Current State of the Nation in Evaluating the Neonatal Brain Who? Why? How?)
Current Pediatric Reviews Optimization and Assay of Antioxidant Potential of Two Penicillium spp. by Different Procedures
Current Biotechnology The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity
Current Neurovascular Research